BS_1AYRM596
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 18.6
- os_event
- false
- age_years
- 8.948
- sex
- M
- race
- White
- new_clusters
- C4
- umap1_2d
- 3.517487895
- umap2_2d
- 3.915350775
- umap1_3d
- 1.011363201
- umap2_3d
- -1.294496735
- umap3_3d
- -3.020985261
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- TNFA_SIGNALING_VIA_NFKB+0.530
- ANGIOGENESIS+0.510
- TGF_BETA_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.390
- IL6_JAK_STAT3_SIGNALING+0.370
- E2F_TARGETS+0.360
- G2M_CHECKPOINT+0.360
- IL2_STAT5_SIGNALING+0.340
- ALLOGRAFT_REJECTION+0.320
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.290
- BILE_ACID_METABOLISM-0.210
- KRAS_SIGNALING_DN-0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.170
- FATTY_ACID_METABOLISM-0.120
- ADIPOGENESIS-0.020
- PEROXISOME-0.020
- DNA_REPAIR+0.000
- XENOBIOTIC_METABOLISM+0.020
- MYC_TARGETS_V2+0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2040 | Med | Medulloblastoma | 0.905 |
| 2 | BS_NR3P3GN2 | high-grade glioma | — | 0.903 |
| 3 | SRR10900575 | — | — | 0.901 |
| 4 | MDT-AP-0309 | Med | Medulloblastoma | 0.884 |
| 5 | F547C7BB-DBF1-4805-A0EA-D8BC36606032 | — | — | 0.881 |
| 6 | TCGA-44-7661-01A-11R-2066-07 | — | cohortA1 | 0.880 |
| 7 | MDT-AP-2086 | Med | Medulloblastoma | 0.880 |
| 8 | TCGA-92-7340-01A-21R-2045-07 | — | cohortSQ1 | 0.876 |
| 9 | C6888F62-AE14-4F73-A1B8-2CB81E2809FD | — | — | 0.871 |
| 10 | SRR934881 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.510 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |